Chemotherapy is estimated at 34.0% in 2026, while liposarcoma represents 24.0% and intravenous delivery 46.0% across pathways requiring pathology and biomarker eligibility plus treatment-center capacity.
Soft Tissue Sarcoma Market Analysis By Disease TypeSoft Tissue Sarcoma Market Analysis By Distribution ChannelSoft Tissue Sarcoma Market Analysis By End UserSoft Tissue Sarcoma Market Analysis By Route Of AdministrationSoft Tissue Sarcoma Market Breakdown By Treatment Type, Disease Type, And RegionSoft Tissue Sarcoma Market Opportunity Matrix Growth Vs Value